Athira Pharma to Participate in Two Upcoming Investor Conferences
Athira Pharma (NASDAQ: ATHA) announced participation in two major investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Athira Pharma (NASDAQ: ATHA) announced participation in two major investor conferences. The first is the Stifel 2022 Virtual CNS Days on March 28-29 at 2:30 PM ET, featuring a fireside chat with key executives including Dr. Mark Litton and Dr. Hans Moebius. The second event is the 21st Annual Needham Virtual Healthcare Conference from April 11-14, with a presentation scheduled for April 14 at 3:00 PM ET. Live webcasts will be available on the Athira website, with recordings accessible for 30 days after.
Details
News Market Reaction – ATHA
The recorded move for ATHA in the trading session of this news was +0.56%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOTHELL, Wash., March 21, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that members of Athira Pharma’s senior management team will participate in the following upcoming investor conferences.
| Stifel 2022 Virtual CNS Days – March 28-29, 2022 | |
| Date/Time: | March 28, 2022 at 2:30 pm Eastern time |
| Format: | Fireside Chat |
| Moderator: | Paul Matteis, Managing Director, Biotechnology Equity Research at Stifel |
| Presenters: | Mark Litton, Ph.D., President & CEO, Hans Moebius, M.D., Ph.D., Chief Medical Officer, Rachel Lenington, Chief Operating Officer |
| 21st Annual Needham Virtual Healthcare Conference – April 11-14, 2022 | |
| Date/Time: | April 14, 2022 at 3:00 pm Eastern time |
| Format: | Fireside Chat |
| Moderator: | Ami Fadia, Managing Director, Senior Biotechnology Equity Research Analyst at Needham & Co. |
| Presenters: | Mark Litton, Ph.D., President & CEO, Hans Moebius, M.D., Ph.D., Chief Medical Officer, Rachel Lenington, Chief Operating Officer |
A live webcast of each fireside chat can be accessed from the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations. An archived replay of the webcast will be available for at least 30 days following the event.
About Athira Pharma, Inc.
Athira Pharma, Inc., headquartered in the Seattle area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, fosgonimeton (ATH-1017), a novel small molecule for Alzheimer’s and Parkinson’s disease dementia and Dementia with Lewy bodies. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn and @athirapharma on Twitter and Instagram.
Investor & Media Contact:
Julie Rathbun
Athira Pharma
Julie.rathbun@athira.com
206-769-9219
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.